Latest close: a new 52-week highSep 8, 2026what changed →
The financials
10x Genomics, Inc. by the numbers
10x Genomics, Inc. (TXG) reported revenue of $151M in Q1 2026 (quarter ended Mar 31, 2026), down 2.6% from the same quarter a year earlier. That came with a gross margin of 70% and net loss of $13M. For the full year FY2025, revenue was $643M (+5.2% year on year) and net income −$44M. Its largest product in Jun 2026 was Chromium Consumables at $88M, 56% of the disclosed total, well ahead of Spatial Consumables at 27%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $151M | $155M | −2.6% |
| Gross profit | $106M | $105M | +0.7% |
| Operating income | −$17M | −$39M | n/a |
| Net income | −$13M | −$34M | n/a |
| Diluted EPS | −$0.10 | −$0.28 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Chromium Consumables | $88M | 56% |
| Spatial Consumables | $42M | 27% |
| Service | $11M | 6.7% |
| Instruments | $7.7M | 4.8% |
| Spatial Instruments | $4.6M | 2.9% |
| Chromium Instruments | $3.1M | 1.9% |
| Licensing And Royalty | $1.9M | 1.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $158.7M (-2.1%)
Service grew +26% year on yearLicensing And Royalty -93% year on year
Segment Latestquarter on quarteryear on year
- Chromium Consumables$88.5M$88.5MQoQ -0.50%year on year +3.1%-0.50%+3.1%
- Spatial Consumables$42.3M$42.3MQoQ +3.4%year on year +16%+3.4%+16%
- Service$10.7M$10.7MQoQ +21%year on year +26%+21%+26%
- Instruments$7.7M$7.7MQoQ -32%year on year -47%-32%-47%
- Spatial Instruments$4.6M$4.6MQoQ -24%year on year -48%-24%-48%
- Chromium Instruments$3.1M$3.1MQoQ -41%year on year -46%-41%-46%
- Licensing And Royalty$1.9M$1.9MQoQ +105%year on year -93%+105%-93%
Health Information Services
Ranks #1 of 13 by Smart Score